AR075047A1 - Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. - Google Patents
Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.Info
- Publication number
- AR075047A1 AR075047A1 ARP100100141A ARP100100141A AR075047A1 AR 075047 A1 AR075047 A1 AR 075047A1 AR P100100141 A ARP100100141 A AR P100100141A AR P100100141 A ARP100100141 A AR P100100141A AR 075047 A1 AR075047 A1 AR 075047A1
- Authority
- AR
- Argentina
- Prior art keywords
- stx2
- seq
- polypeptide
- protein
- antibody
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 13
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 13
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 13
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 108010079723 Shiga Toxin Proteins 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108010090763 Shiga Toxin 2 Proteins 0.000 abstract 13
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000001542 size-exclusion chromatography Methods 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 abstract 1
- 108010091769 Shiga Toxin 1 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14689209P | 2009-01-23 | 2009-01-23 | |
| US21008209P | 2009-03-13 | 2009-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075047A1 true AR075047A1 (es) | 2011-03-02 |
Family
ID=42356196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100141A AR075047A1 (es) | 2009-01-23 | 2010-01-22 | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8969529B2 (enExample) |
| EP (1) | EP2381954B8 (enExample) |
| JP (1) | JP5773886B2 (enExample) |
| KR (1) | KR101832499B1 (enExample) |
| CN (1) | CN102292098A (enExample) |
| AR (1) | AR075047A1 (enExample) |
| AU (1) | AU2010206800B2 (enExample) |
| BR (1) | BRPI1007230B1 (enExample) |
| CA (1) | CA2748873C (enExample) |
| CL (1) | CL2011001769A1 (enExample) |
| ES (1) | ES2614803T3 (enExample) |
| MX (1) | MX2011007866A (enExample) |
| NZ (1) | NZ593926A (enExample) |
| PE (1) | PE20120425A1 (enExample) |
| RU (1) | RU2011126896A (enExample) |
| WO (1) | WO2010085539A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1229045A1 (en) * | 2001-02-01 | 2002-08-07 | Institut Curie | Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| MX2008013363A (es) | 2006-04-20 | 2009-03-26 | Jackson H M Found Military Med | Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga. |
| CA2748873C (en) | 2009-01-23 | 2017-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
| US9513287B1 (en) * | 2012-09-28 | 2016-12-06 | The United States Of America, As Represented By The Secretary Of Agriculture | High affinity monoclonal antibodies for detection of shiga toxin 2 |
| US9310368B1 (en) * | 2012-09-28 | 2016-04-12 | The United States Of America, As Represented By The Secretary Of Agriculture | High affinity monoclonal antibodies for detection of Shiga toxin 2 (STX2) |
| CN105051067B (zh) * | 2013-03-12 | 2020-04-17 | 分子模板公司 | 用于引起细胞内化的cd20结合免疫毒素及其使用方法 |
| CN103343164B (zh) * | 2013-06-17 | 2016-05-18 | 武汉轻工大学 | 产志贺毒素大肠杆菌多重pcr检测方法、试剂盒及应用 |
| RU2573924C2 (ru) * | 2013-07-11 | 2016-01-27 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2) |
| KR102500408B1 (ko) * | 2014-01-27 | 2023-02-16 | 몰레큘러 템플레이츠, 인코퍼레이션. | 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드 |
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| CN113831416A (zh) * | 2014-06-11 | 2021-12-24 | 分子模板公司 | 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子 |
| CN104558167B (zh) * | 2014-12-26 | 2017-12-26 | 江苏省疾病预防控制中心 | 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用 |
| ES2856457T3 (es) | 2015-02-05 | 2021-09-27 | Molecular Templates Inc | Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN107849096B (zh) | 2015-05-30 | 2022-05-24 | 分子模板公司 | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN114773439A (zh) | 2016-12-07 | 2022-07-22 | 分子模板公司 | 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子 |
| MX2019008840A (es) | 2017-01-25 | 2019-09-09 | Molecular Templates Inc | Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+. |
| AU2019257343A1 (en) | 2018-04-17 | 2020-09-10 | Molecular Templates, Inc. | HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds |
| CN115856296B (zh) * | 2022-12-16 | 2023-07-25 | 华北理工大学 | 抗志贺氏菌的单克隆抗体及其检测中的应用 |
| CN120647752B (zh) * | 2025-08-19 | 2025-10-28 | 中国人民解放军军事科学院军事医学研究院 | 一种抗ⅱ型志贺毒素的单克隆抗体及其相关产品和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5164298A (en) | 1988-06-24 | 1992-11-17 | Hsc Research Development Corporation | Verocytotoxin receptor assay |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5552144A (en) * | 1992-01-22 | 1996-09-03 | Microcarb, Inc. | Immunogenic shiga-like toxin II variant mutants |
| US5747272A (en) | 1994-02-14 | 1998-05-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Detection of shiga-like toxins of enterohemoragic Escherichia coli |
| US5968894A (en) | 1994-02-22 | 1999-10-19 | Lingwood; Clifford A. | Verotoxin pharmaceutical compositions and medical treatments therewith |
| EP0929679A2 (en) | 1996-09-10 | 1999-07-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof |
| WO1998020903A1 (en) | 1996-11-15 | 1998-05-22 | Trustees Of Tufts College | Humanized neutralizing antibodies against hemolytic uremic syndrome |
| US7910096B2 (en) | 1996-11-15 | 2011-03-22 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic uremic syndrome |
| US20020160005A1 (en) * | 1996-11-15 | 2002-10-31 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic urmec syndrome |
| US20030170248A1 (en) * | 1997-12-23 | 2003-09-11 | Jeffrey R. Stinson | Humanized monoclonal antibodies that protect against shiga toxin induced disease |
| IL139571A0 (en) | 1998-05-20 | 2002-02-10 | Teijin Ltd | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same |
| ATE504312T1 (de) * | 2003-07-21 | 2011-04-15 | Intervet Int Bv | Hybrid-toxine mit shiga-artigen toxin- untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus |
| AU2004293502B2 (en) | 2003-11-28 | 2010-12-02 | National Research Council Of Canada | Anticarcinoma antibodies and uses thereof |
| JP2008507253A (ja) | 2004-02-06 | 2008-03-13 | ナイモックス コーポレーション | ヒト化抗体 |
| CA2458084A1 (en) | 2004-03-12 | 2005-09-12 | Dalton Chemical Laboratories Inc. | Novel process for octreotide synthesis |
| WO2006091677A1 (en) * | 2005-02-22 | 2006-08-31 | Jean Gariepy | Yeast strains expressing ribosome-inactivating protein domain and method of using same |
| ES2532985T3 (es) | 2006-02-16 | 2015-04-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Proteínas quiméricas de toxoide de Shiga |
| MX2008013363A (es) | 2006-04-20 | 2009-03-26 | Jackson H M Found Military Med | Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga. |
| JP2009538916A (ja) | 2006-05-31 | 2009-11-12 | タリオン ファーマシューティカルズ インコーポレーテッド | 志賀毒素関連病状を治療するための方法、組成物、およびキット |
| US20090258010A1 (en) | 2006-05-31 | 2009-10-15 | Thallion Pharmaceuticals, Inc. | Methods, compositions, and kits for treating shiga toxin associated conditions |
| AU2007339753A1 (en) * | 2006-12-29 | 2008-07-10 | Osprey Pharmaceuticals Usa, Inc. | Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof |
| US20100298238A1 (en) | 2007-10-08 | 2010-11-25 | Rutgers, The State University | Nontoxic shiga-like toxin mutant compositions and methods |
| CN101314616B (zh) * | 2008-05-30 | 2011-05-11 | 中国人民解放军第三军医大学 | 肠出血性大肠杆菌o157:h7志贺毒素ⅱb表位肽及其应用 |
| US20110165680A1 (en) * | 2008-09-12 | 2011-07-07 | Scarab Genomics, Llc | Clean genome bactofection |
| CA2748873C (en) | 2009-01-23 | 2017-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods and compositions based on shiga toxin type 2 protein |
-
2010
- 2010-01-21 CA CA2748873A patent/CA2748873C/en active Active
- 2010-01-21 CN CN2010800052595A patent/CN102292098A/zh active Pending
- 2010-01-21 AU AU2010206800A patent/AU2010206800B2/en active Active
- 2010-01-21 EP EP10733840.2A patent/EP2381954B8/en active Active
- 2010-01-21 PE PE2011001368A patent/PE20120425A1/es not_active Application Discontinuation
- 2010-01-21 RU RU2011126896/10A patent/RU2011126896A/ru not_active Application Discontinuation
- 2010-01-21 US US13/142,556 patent/US8969529B2/en active Active
- 2010-01-21 ES ES10733840.2T patent/ES2614803T3/es active Active
- 2010-01-21 JP JP2011548095A patent/JP5773886B2/ja active Active
- 2010-01-21 MX MX2011007866A patent/MX2011007866A/es unknown
- 2010-01-21 NZ NZ593926A patent/NZ593926A/xx not_active IP Right Cessation
- 2010-01-21 KR KR1020117019455A patent/KR101832499B1/ko not_active Expired - Fee Related
- 2010-01-21 WO PCT/US2010/021610 patent/WO2010085539A1/en not_active Ceased
- 2010-01-21 BR BRPI1007230-6A patent/BRPI1007230B1/pt not_active IP Right Cessation
- 2010-01-22 AR ARP100100141A patent/AR075047A1/es not_active Application Discontinuation
-
2011
- 2011-07-21 CL CL2011001769A patent/CL2011001769A1/es unknown
-
2015
- 2015-02-23 US US14/628,667 patent/US9801931B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5773886B2 (ja) | 2015-09-02 |
| BRPI1007230B1 (pt) | 2019-11-12 |
| EP2381954A1 (en) | 2011-11-02 |
| US8969529B2 (en) | 2015-03-03 |
| PE20120425A1 (es) | 2012-05-03 |
| EP2381954B1 (en) | 2016-11-02 |
| RU2011126896A (ru) | 2013-02-27 |
| EP2381954B8 (en) | 2017-01-25 |
| CA2748873A1 (en) | 2010-07-29 |
| US20160243210A1 (en) | 2016-08-25 |
| KR20110119725A (ko) | 2011-11-02 |
| WO2010085539A1 (en) | 2010-07-29 |
| KR101832499B1 (ko) | 2018-02-26 |
| CN102292098A (zh) | 2011-12-21 |
| CA2748873C (en) | 2017-09-12 |
| US20110318357A1 (en) | 2011-12-29 |
| ES2614803T3 (es) | 2017-06-02 |
| MX2011007866A (es) | 2011-10-06 |
| BRPI1007230A2 (pt) | 2016-02-16 |
| NZ593926A (en) | 2013-03-28 |
| US9801931B2 (en) | 2017-10-31 |
| EP2381954A4 (en) | 2012-08-01 |
| AU2010206800A1 (en) | 2011-07-28 |
| AU2010206800B2 (en) | 2016-06-30 |
| CL2011001769A1 (es) | 2012-08-31 |
| JP2012515551A (ja) | 2012-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075047A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| Vilanova et al. | Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2 | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| JP2012515551A5 (enExample) | ||
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| BR112014030797A2 (pt) | epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| AR045056A1 (es) | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf | |
| CO6251322A2 (es) | Polipeptidos dominios variables de anticuerpos y antagonistas | |
| CL2008002668A1 (es) | Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp. | |
| PE20081625A1 (es) | Proteinas de union al antigeno del receptor a de la il-17 | |
| BRPI0911699B8 (pt) | vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
| BRPI0619595A8 (pt) | anticorpo neutralizante, epítopo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado ou completamente humano | |
| PE20191662A1 (es) | Anticuerpos anti-il-5 | |
| BR112022009570A2 (pt) | Anticorpo anti-¿v¿6 isolado ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-¿v¿6 ou fragmento de ligação ao antígeno, para produção de um conjugado anticorpo anti-¿v¿6-fármaco e para tratamento de câncer em um indivíduo, e, composição farmacêutica | |
| PE20030473A1 (es) | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| CN105518025A (zh) | 人抗IFN-α抗体 | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| PE20230384A1 (es) | Anticuerpos cd163 o proteinas de union | |
| McConnell et al. | Expression, purification, and refolding of biologically active Acinetobacter baumannii OmpA from Escherichia coli inclusion bodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |